After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
Data on the group’s sickle cell project do not feature in the regular abstracts, while Bluebird walks away from its short hairpin contender.
A takeover symbolising the push to beef up Sanofi’s oncology pipeline is taken back to the drawing board.
Two Astrazeneca breast cancer projects record apparent pivotal successes in settings where Roche had failed.
Bristol Myers Squibb has been trying for years to hit LPA1 with small molecules, but an acquisition by Abbvie signals a new approach.
Hitting two targets with one molecule is all the rage in oncology, but Roche and others have taken this work into other disease areas.